LONDON, Sept 4 (Reuters) - Britain's health regulator

said on Wednesday that the available data does not establish a

link between a popular class of diabetes and obesity drugs,

including Novo Nordisk's Wegovy, and suicidal

thoughts.

The Medicines and Healthcare products Regulatory Agency

(MHRA) began a review of safety data for the class of drugs,

known as GLP-1 receptor agonists, more than a year ago after

some patients reported suicidal or self-harming thoughts.

"We conclude that the available data does not support a

causal association between GLP-1 receptor agonists and suicide,

suicidal ideation, self-injury and depression, and therefore no

updates to the product information is warranted at this time,"

it said in a statement.

The UK review began weeks after similar action by the

European Union. It included Wegovy and another Novo Nordisk

drug, Ozempic, which contains the active ingredient semaglutide

and is approved to treat Type 2 diabetes.

The EU drug regulator said in April that its own review had

found no evidence that the class of medicines are linked to

suicidal thoughts.

The U.S. Food and Drug Administration said in January that

its preliminary review had not found evidence that GLP-1 drugs

were linked to suicidal thoughts, but that it will continue to

study the issue.